BioScrip (NASDAQ:BIOS) Announces Earnings Results

BioScrip (NASDAQ:BIOS) released its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04), Fidelity Earnings reports. The business had revenue of $191.52 million during the quarter, compared to the consensus estimate of $185.73 million.

Shares of BioScrip stock traded up $0.02 on Wednesday, reaching $2.90. 295,431 shares of the company were exchanged, compared to its average volume of 913,941. The stock has a 50-day moving average price of $2.55. The stock has a market capitalization of $359.24 million, a price-to-earnings ratio of -5.92 and a beta of 0.68. BioScrip has a 1-year low of $1.56 and a 1-year high of $4.14.

A number of brokerages have recently weighed in on BIOS. TheStreet cut Red Lion Hotels from a “c” rating to a “d+” rating in a research report on Wednesday, April 3rd. Barrington Research reiterated a “buy” rating and set a $4.00 price target on shares of BioScrip in a research report on Friday, May 3rd. Zacks Investment Research upgraded Hanmi Financial from a “sell” rating to a “hold” rating in a research report on Thursday, June 20th. Finally, BidaskClub upgraded WhiteHorse Finance from a “sell” rating to a “hold” rating in a research report on Thursday, July 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $4.60.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

See Also: Preferred Stock

Earnings History for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with's FREE daily email newsletter.